FDA approves Watson asthma generic

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug designed to treat asthma in children.



Watson Pharmaceuticals announced Wednesday the approval of budesonide inhalation suspension in the 0.25-mg/2-mL and 0.5-mg/2-mL strengths. The drug is used to control and prevent asthma symptoms in children ages 12 months to 8 years.



The drug is a generic version of AstraZeneca's Pulmicort Respules, which had sales of $1.1 billion during the 12-month period ended in May.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.